Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

Westhovens, René; Ravelingien, Isabelle; Vandevyvere, K.; Pansar, I; Purcaru, O.; Kumke, T.; Gyselbrecht, Lieve

doi:10.1080/17843286.2018.1509923

Cited by 4 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-three studies on costs of WP were cross-sectional or retrospective and therefore did not comply with inclusion criteria to assess general methodological choices. A total of 81 studies were included in our analysis (flowchart in online supplemental figure S2): 58 for extraction of general methodological choices,16–73 23 for outcome reporting studies on costs of work productivity16 74–96 and one providing information on both outcomes 16…”

Section: Resultsmentioning

confidence: 99%

“…The 58 IA studies appraising general methodological issues comprised 46 longitudinal observational studies16 17 20 23 26 27 29–31 33 34 39–47 50 51 55–59 61 63 65 66 68 70–73 and 22 RCTs 18 19 21 22 24 25 28 32 35–38 48 49 52–54 60 62 64 67 69. The characteristics of included studies are provided in online supplemental table S1.…”

Section: Resultsmentioning

confidence: 99%

“…Most of the IA studies were on rheumatoid arthritis (RA) (n=33, 57%),16 17 21–24 27–29 31–34 36 37 39–41 44–47 49 52–54 56 57 61 64 68 69 72 followed by axial spondyloarthritis (axSpA) (n=16, 28%)18 19 30 38 50 51 59 60 62 63 65–67 70 71 73 and psoriatic arthritis (PsA) (n=6, 10%),25 35 43 48 55 58 and finally, two studies assessed two diagnostic groups: RA and axSpA,42 and axSpA and PsA 26…”

Section: Resultsmentioning

confidence: 99%

“…Assessing sick leave only among employed patients: 43/46 (93%)18–22 24–27 29 31–39 42–47 50–56 58–60 63 65–69 71 73…”

Section: Methodsmentioning

confidence: 99%

“…Assessing presenteeism among employed patients that were not in sick leave: 37/40 (90%)18–22 24–26 31–39 42 43 50–56 58–60 62–64 67–69 71 73…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo summarise the methodological aspects in studies with work participation (WP) as outcome domain in inflammatory arthritis (IA) and other chronic diseases.MethodsTwo systematic literature reviews (SLRs) were conducted in key electronic databases (2014–2019): search 1 focused on longitudinal prospective studies in IA and search 2 on SLRs in other chronic diseases. Two reviewers independently identified eligible studies and extracted data covering pre-defined methodological areas.ResultsIn total, 58 studies in IA (22 randomised controlled trials, 36 longitudinal observational studies) and 24 SLRs in other chronic diseases were included. WP was the primary outcome in 26/58 (45%) studies. The methodological aspects least accounted for in IA studies were as follows (proportions of studies positively adhering to the topic are shown): aligning the studied population (16/58 (28%)) and sample size calculation (8/58 (14%)) with the work-related study objective; attribution of WP to overall health (28/58 (48%)); accounting for skewness of presenteeism/sick leave (10/52 (19%)); accounting for work-related contextual factors (25/58 (43%)); reporting attrition and its reasons (1/58 (2%)); reporting both aggregated results and proportions of individuals reaching predefined meaningful change or state (11/58 (16%)). SLRs in other chronic diseases confirmed heterogeneity and methodological flaws identified in IA studies without identifying new issues.ConclusionHigh methodological heterogeneity was observed in studies with WP as outcome domain. Consensus around various methodological aspects specific to WP studies is needed to improve quality of future studies. This review informs the EULAR Points to Consider for conducting and reporting studies with WP as an outcome in IA.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Assessing sick leave only among employed patients: 43/46 (93%)18–22 24–27 29 31–39 42–47 50–56 58–60 63 65–69 71 73…”

Section: Methodsmentioning

confidence: 99%

“…Assessing presenteeism among employed patients that were not in sick leave: 37/40 (90%)18–22 24–26 31–39 42 43 50–56 58–60 62–64 67–69 71 73…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

et al. 2021

View full text Add to dashboard Cite

show abstract

Certolizumab pegol

2019

Reactions Weekly

View full text Add to dashboard Cite

Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study

Kameda,

Nishida,

Nanki

et al. 2024

Modern Rheumatology

View full text Add to dashboard Cite

Objectives To report up to 3-year safety and effectiveness of certolizumab pegol (CZP) in Japanese patients with rheumatoid arthritis from a postmarketing surveillance study. Methods Patients enrolled previously completed 24 weeks of CZP in the 24-week postmarketing surveillance study. Adverse drug reactions (ADRs) were recorded for patients who received ≥1 CZP dose. Effectiveness outcomes were 28-joint Disease Activity Score with erythrocyte sedimentation rate and European Alliance of Associations for Rheumatology response. Week 24–156 safety and Week 0–52 effectiveness data are reported here. Results A total of 781 patients were enrolled, with 735 and 376 patients evaluated for safety and effectiveness, respectively. Within the safety set, 17.8% (131/735) of patients reported ADRs; 9.4% (69/735) reported serious ADRs. Among patients with history of respiratory, thoracic, and mediastinal disorders, 38.4% (28/73) reported ADRs. The most frequent ADRs were infections and infestations (11.8%; 87/735); skin and subcutaneous tissue disorders (1.9%; 14/735); respiratory, thoracic, and mediastinal disorders (1.6%; 12/735). Mean 28-joint Disease Activity Score with erythrocyte sedimentation rate reduced from 4.6 (Week 0) to 2.8 (Week 52). At Week 52, 51.8% (161/311) of patients achieved European Alliance of Associations for Rheumatology Good response. Conclusions The long-term safety and effectiveness of CZP in the real-world setting in Japan were consistent with previously reported data; no new safety signals were identified.

show abstract

Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

Abstract: CZP has a positive impact on productivity and social participation in patients with RA in the Belgian daily practice setting, with safety and efficacy profiles that mirror those observed in the trial setting.

Cited by 4 publications

References 44 publications

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

Certolizumab pegol

Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study

Contact Info

Product

Resources

About